Semaglutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
A modified GLP-1 receptor agonist marketed for weight loss and type 2 diabetes. Human evidence is strong, with large trials backing weight loss, glycemic control, and cardiovascular benefits, though neuroprotective claims stay speculative. Main risk is GI side effects in many users, plus a boxed thyroid-tumor warning (animal studies) and contraindication in MEN 2 or medullary thyroid cancer history. FDA-approved; obtain only through a licensed prescriber.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Semaglutide is a lab-made version of GLP-1, a natural hormone your body releases after eating to signal fullness. It's nearly identical to the natural hormone (94% match) but engineered to last much longer in the body: about seven days per dose instead of minutes. Sold under the brand names Ozempic, Wegovy, and Rybelsus, it is FDA-approved for type 2 diabetes, weight management, and reducing the risk of heart attack and stroke.
How it works in the body
A GLP-1 receptor agonist with 94% similarity to natural GLP-1. A key modification (aminobutyric acid at position 8 + C18 fatty diacid) provides albumin binding for a 7-day half-life. It activates GLP-1 receptors in the pancreas (insulin), brain (appetite suppression), and heart (cardioprotection).
Research overview
Semaglutide works by mimicking your body's natural fullness signal. It prompts the pancreas to release insulin when blood sugar is high, suppresses the hormone that raises blood sugar (glucagon), slows the rate food leaves your stomach (so you feel full longer), and acts on appetite centers in the brain to reduce hunger. A fatty acid chain attached to the molecule lets it bind to a blood protein called albumin, extending its activity to about one week per dose. It also has anti-inflammatory effects. Semaglutide has one of the strongest clinical evidence bases of any peptide, with over 40,000 participants across dozens of large-scale trials.
Who researches Semaglutide?
Commonly researched by
People researching weight management options
Studied for effects on body composition, appetite regulation, or metabolic rate.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
People researching blood sugar regulation
Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.
Important considerations for
Those with Personal/family history of medullary thyroid carcinoma (MTC)
AbsoluteGLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.
Those with History of pancreatitis
HighGLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.
Those with Severe gastroparesis
HighSemaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.
Those who are pregnant or breastfeeding
AbsoluteDiscontinue at least 2 months before planned conception. Animal studies show fetal harm.
Those with Type 1 diabetes
AbsoluteNot indicated for T1DM. Risk of diabetic ketoacidosis.
Those with Severe renal impairment
ModerateGI side effects (nausea, vomiting) may worsen dehydration and renal function.
Safety & interactions
Do not use if
Personal/family history of medullary thyroid carcinoma (MTC)
AbsoluteGLP-1 agonists caused thyroid C-cell tumors in rodents. Contraindicated in MTC or MEN2 syndrome.
Type 1 diabetes
AbsoluteNot indicated for T1DM. Risk of diabetic ketoacidosis.
History of pancreatitis
HighGLP-1 agonists may increase pancreatitis risk. Use with extreme caution if prior pancreatitis.
Severe gastroparesis
HighSemaglutide slows gastric emptying. Can worsen severe gastroparesis significantly.
Severe renal impairment
ModerateGI side effects (nausea, vomiting) may worsen dehydration and renal function.
General cautions
Pregnancy or planning pregnancy
AbsoluteDiscontinue at least 2 months before planned conception. Animal studies show fetal harm.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(7)
Rated by level of concern
GI side effects: nausea (20-44%), vomiting, diarrhea, constipation
HighPMID 33567185 (STEP 1); FDA Wegovy/Ozempic prescribing information, Adverse Reactions
Boxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)
ModerateFDA Ozempic/Wegovy prescribing information, Boxed Warning; SUSTAIN/STEP program safety data
Pancreatitis risk (rare)
LowFDA Ozempic prescribing information, Warnings and Precautions (Pancreatitis); PMID 37952131 (SELECT safety)
Gallbladder disease risk
ModeratePMID 33567185 (STEP 1); He et al., JAMA Intern Med 2022, GLP-1 RA gallbladder/biliary meta-analysis
Acute kidney injury (rare, usually from dehydration due to GI effects)
LowFDA Ozempic prescribing information, Warnings and Precautions (Acute Kidney Injury); Perkovic et al., NEJM 2024 (FLOW)
Diabetic retinopathy complications
ModeratePMID 27633186 (SUSTAIN-6); FOCUS trial (NCT03811561); FDA Ozempic prescribing information, Warnings and Precautions (Diabetic Retinopathy Complications)
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
HighFDA Ozempic/Wegovy prescribing information, Contraindications
Interaction summary(9)
Rated by direction with this peptide
Insulin (basal or prandial)
CautionHighAdditive glucose lowering causes clinically significant hypoglycemia; the label directs reducing the insulin dose when semaglutide is added, and this is one of the few genuinely dangerous, well-documented interactions.
FDA Ozempic prescribing information, Warnings and Precautions (Hypoglycemia) and Dosage and Administration
Sulfonylureas (glipizide, glyburide, glimepiride)
CautionHighInsulin-secretagogue plus incretin agonist markedly raises severe hypoglycemia risk; sulfonylurea dose reduction or discontinuation is standard practice at semaglutide initiation.
FDA Ozempic prescribing information, Warnings and Precautions (Hypoglycemia); PMID 27633186 (SUSTAIN-6 hypoglycemia data)
General anesthesia and procedural sedation
CautionModerateDelayed gastric emptying can leave residual gastric contents despite standard fasting, and the ASA issued 2023 consensus guidance on holding GLP-1 agonists before elective procedures because of pulmonary aspiration risk; endoscopy series have documented retained food.
American Society of Anesthesiologists, Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists (June 2023)
Warfarin and other narrow-therapeutic-index oral drugs
CautionLowSemaglutide slows gastric emptying and can alter the rate of oral absorption. Dedicated PK studies with warfarin showed no clinically relevant change in overall exposure or INR, so this is a monitoring-level precaution during initiation and titration rather than a demonstrated clinical interaction.
FDA Ozempic prescribing information, Drug Interactions and Clinical Pharmacology (drug interaction studies)
Levothyroxine (particularly with oral semaglutide/Rybelsus)
CautionModerateThe SNAC absorption enhancer in oral semaglutide increases total levothyroxine exposure by roughly 33%, so thyroid function should be monitored; the two must also be dosed apart given Rybelsus's strict fasting-plus-30-minute administration requirement.
FDA Rybelsus prescribing information, Drug Interactions
Diuretics, ACE inhibitors/ARBs, and NSAIDs during GI illness
CautionModerateVolume depletion from semaglutide-induced vomiting or diarrhea, added to these agents, is the usual pathway to acute kidney injury; sick-day rules apply rather than avoidance. Mechanistic and postmarketing rather than trial-demonstrated.
FDA Ozempic prescribing information, Warnings and Precautions (Acute Kidney Injury)
Other GLP-1 receptor agonists and DPP-4 inhibitors
CautionLowPharmacologically redundant - combining offers no incremental efficacy while compounding GI adverse effects, and co-prescription with another GLP-1 RA is not recommended. This is therapeutic duplication rather than a toxicity interaction.
ADA Standards of Care, Pharmacologic Approaches to Glycemic Treatment
SGLT2 inhibitors (empagliflozin, dapagliflozin)
SynergisticLowComplementary mechanisms with additive glycemic and weight benefit and no hypoglycemia liability; randomized data (SUSTAIN 9: semaglutide added to background SGLT2 inhibitor) support the combination, and both classes independently carry cardiovascular and renal outcome evidence.
Zinman et al., Lancet Diabetes Endocrinol 2019 (SUSTAIN 9); ADA Standards of Care
Combined oral contraceptives
NeutralLowDedicated PK studies found no clinically relevant reduction in ethinyl estradiol or levonorgestrel exposure with semaglutide, so no backup contraception is required on pharmacokinetic grounds - though pregnancy must be avoided and the drug stopped 2 months before a planned pregnancy.
FDA Ozempic prescribing information, Drug Interactions and Use in Specific Populations (Pregnancy)
Known risks(7)
GI side effects: nausea (20-44%), vomiting, diarrhea, constipation
Boxed warning: thyroid C-cell tumors in animal studies (human relevance unclear)
Pancreatitis risk (rare)
Gallbladder disease risk
Acute kidney injury (rare, usually from dehydration due to GI effects)
Diabetic retinopathy complications
Contraindicated: personal/family history of medullary thyroid carcinoma or MEN 2
Drug interactions(3)
Tirzepatide
Both are GLP-1 agonists. Combining would increase GI side effects and hypoglycemia risk.
Insulin
Increased hypoglycemia risk. Dose reduction of insulin may be needed.
Oral medications
Slowed gastric emptying may affect absorption of oral drugs. Take oral meds 1+ hour before semaglutide.
Research & benefits
Evidence base
- Evidence Level
- Level 1 — Strong
- Total Studies
- 288
- Human Participants
- 40000
Over 40,000 participants across dozens of Phase 3 RCTs. Evidence supports weight loss, T2DM, CV risk reduction, CKD.
Researched for(7)
Rated by confidence in the evidence
Significant weight loss
HighLarge randomized trial showed 14.9% body weight loss versus 2.4% with placebo.
PMID 33567185 (Wilding et al., NEJM 2021, STEP 1); FDA Wegovy prescribing information
Type 2 diabetes control
HighMultiple large trials showed HbA1c reductions of 1 to 1.8 percentage points versus placebo.
FDA Ozempic and Rybelsus prescribing information (Clinical Studies); SUSTAIN and PIONEER phase 3 program (e.g. Ahren et al., Lancet Diabetes Endocrinol 2017, SUSTAIN 2)
Cardiovascular risk reduction
HighTwo large outcome trials showed roughly 20 to 26% fewer major cardiovascular events.
PMID 27633186 (Marso et al., NEJM 2016, SUSTAIN-6); PMID 37952131 (Lincoff et al., NEJM 2023, SELECT)
Kidney disease protection
HighLarge kidney-outcomes trial stopped early after showing a 24% reduction in kidney disease progression.
Perkovic et al., NEJM 2024 (FLOW); NCT03819153
Heart failure improvement
HighTrials show improved heart failure symptoms and function in obesity-related HFpEF, not mortality.
Kosiborod et al., NEJM 2023 (STEP-HFpEF, NCT04788511); Kosiborod et al., NEJM 2024 (STEP-HFpEF DM, NCT04916470)
Neuroprotective potential
SpeculativePreliminary evidence only; phase 3 Alzheimer's trials failed to show significant benefit.
NCT04777396 (EVOKE), NCT04777409 (EVOKE+), Novo Nordisk topline announcement 2025
Anti-inflammatory effects
MediumLarge trials show reduced inflammatory markers, but no clinical inflammatory-disease outcome tested.
PMID 37952131 (SELECT, hsCRP secondary endpoint); PMID 33567185 (STEP 1, CRP secondary endpoint)
Benefits(7)
Significant weight loss
Type 2 diabetes control
Cardiovascular risk reduction
Kidney disease protection
Heart failure improvement
Neuroprotective potential
Anti-inflammatory effects
Key studies(5)
Wilding JPH et al.
NEJM
2021
14.9% mean weight loss vs 2.4% placebo over 68 weeks
Lincoff AM et al.
NEJM
2023
20% MACE reduction in 17,604 patients
Marso SP et al.
NEJM
2016
26% CV event reduction in 3,297 patients
Perkovic V et al.
NEJM
2024
24% reduction in major kidney events
Wharton S et al.
Lancet Diabetes Endocrinol
2025
21% mean weight loss, 90%+ achieved >=5%
What research suggests over time
Weeks 2-4
STEP-1 (NEJM 2021)Reduced food cravings and ~2% weight loss during the initial low-dose titration phase.
Months 2-3
STEP-1 / SUSTAIN~6-9% weight loss as the dose climbs toward the target; meaningful A1c improvements in patients with diabetes.
Long-term
Phase 3 RCTMean 14.9% weight loss at 68 weeks in STEP 1. SELECT trial showed 20% MACE risk reduction over ~3 years.
Prescribing labels
FDA-Approved Labels
This page does not list doses. Each product below has an FDA label with its prescribing information.
- Protocol
- Ozempic (semaglutide) injection
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
- Protocol
- Wegovy (semaglutide) injection and tablets
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
- Protocol
- Rybelsus and Ozempic (semaglutide) tablets
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
Monitoring & labs
Baseline before starting, then per marker schedule during protocol.
Baseline labs(7)
Complete Blood Count (CBC)
Optimal All markers within mid-rangeEstablishes baseline for detecting hematological changes.
Lab normal Standard reference ranges
Comprehensive Metabolic Panel (CMP)
Optimal Liver enzymes <25, glucose 75–90, eGFR >90Liver and kidney function baseline.
Lab normal Standard reference ranges
Fasting glucose + HbA1c
Optimal 75–90 mg/dLBaseline metabolic markers — critical for tracking glucose regulation changes.
Lab normal 65–99 mg/dL
Lipid panel
Optimal ApoB <80, TG <80, HDL >55Cholesterol and triglyceride baseline for tracking cardiovascular metabolic effects.
Lab normal TC <200, LDL <100, HDL >40, TG <150
Thyroid panel (TSH, free T3/T4)
Optimal TSH 1.0–2.0; Free T3 upper third of rangeThyroid function can be affected by metabolic peptides.
Lab normal TSH 0.4–4.5
Amylase + Lipase
Optimal Both within mid-rangeBaseline pancreatic markers — this peptide carries a documented pancreatitis risk.
Lab normal Standard ranges
Calcitonin
Optimal Under 5 pg/mLBaseline thyroid C-cell marker — this peptide carries a thyroid tumor risk warning.
Lab normal Under 10 pg/mL (men)
Ongoing tracking(5)
Fasting glucose + HbA1c
Every 4-8 weeksOptimal 75–90 mg/dLTrack glucose regulation changes during protocol.
Lab normal 65–99 mg/dL
Lipid panel
Every 8-12 weeksOptimal ApoB <80, TG <80, HDL >55Monitor cholesterol and triglyceride response.
Lab normal TC <200, LDL <100, HDL >40, TG <150
Liver enzymes (ALT/AST)
Every 8 weeksOptimal ALT & AST under 25 U/LHepatic function monitoring during metabolic modulation.
Lab normal ALT 7–56, AST 10–40 U/L
Amylase + Lipase
Every 8-12 weeksOptimal Both within mid-rangePancreatic enzyme monitoring — pancreatitis risk.
Lab normal Standard ranges
Calcitonin
Every 12 weeksOptimal Under 5 pg/mLThyroid C-cell monitoring — MTC risk.
Lab normal Under 10 pg/mL (men)
Retest schedule(6)
Baseline
critical
Before starting
Full baseline + thyroid panel, lipase, amylase, HbA1c, lipid panel.
Early follow-up
critical
Week 4
Recheck lipase, amylase, glucose. Most early-protocol concerns surface here.
Second check
critical
Week 8
Recheck metabolic markers and GI tolerance.
Mid-protocol
critical
Week 12
Comprehensive retest. Track HbA1c, weight, lipids, thyroid.
Ongoing
standard
Every 12 weeks
Sustained metabolic monitoring during chronic use.
Post-protocol
standard
4-6 weeks after stopping
Track for weight regain and metabolic rebound.
When to stop and reassess(7)
ALT or AST
stopAbove 2× upper limit of normal (>~80 U/L)
Stop protocol and consult a provider — possible drug-induced liver injury.
eGFR
stopDrop of >15 mL/min/1.73m² from baseline, or below 60
Stop protocol and consult a provider — possible kidney function decline.
Symptoms
stopNew severe symptoms correlating with lab changes
Stop protocol and seek medical evaluation immediately.
Lipase or amylase
stopAbove 3× upper limit of normal
Stop protocol and seek urgent medical evaluation — possible pancreatitis.
Calcitonin
consultAbove 10 pg/mL or rising trend
Consult an endocrinologist — possible thyroid C-cell stimulation.
Heart rate
consultSustained >100 bpm or new palpitations
Consult a provider — GLP-1 agonists can affect cardiac rhythm.
Lipase
stopAbove 3× upper limit of normal
Stop protocol and seek urgent medical evaluation — pancreatitis risk documented.
Lab monitoring helps track your body's response to Semaglutide. Any unexplained changes should prompt discussion with your prescribing provider.
Regulation & availability
Why researchers look at it
One of the most extensively studied weight-loss medicines, with 40,000+ trial participants showing 15-20% sustained weight loss and a 20% reduction in heart attacks and strokes. Research continues in addiction and liver disease; phase 3 Alzheimer's trials did not show clinical benefit. An oral formulation approved in late 2025 could widen access.
- Estimated cost
- Self-pay $349/mo for Wegovy or Ozempic pens ($399/mo for Wegovy HD, the highest Wegovy dose; $499/mo for Ozempic at its highest dose), pills from $149/mo (NovoCare, checked 21 Oct 2026); $60-299/mo compounded through telehealth; some providers add a membership fee
- FDA status
- Fully FDA-approved. Ozempic (Dec 2017), Rybelsus (Sept 2019), Wegovy (June 2021), Oral Wegovy (Dec 2025), a higher-dose Wegovy (early 2026). WHO Essential Medicine.
- WADA status
- Not prohibited under the 2026 WADA rules. Semaglutide markers are monitored in and out of competition. A TUE is not required for semaglutide itself.
- Prescribability
- FDA-approved prescription drug: Ozempic, Wegovy and Rybelsus. Compounding remains subject to federal restrictions; shortage-related exceptions ended in 2025.
- Availability
- Available by prescription as injectable and oral products. Compounding restrictions predate February 2026; 503A patient-specific exceptions require applicable conditions, including a documented significant difference when relevant.
International status
EU
EMA-approved (Ozempic, Wegovy, Rybelsus)
UK
MHRA-approved
US
FDA-approved (Ozempic, Wegovy, Rybelsus)
Japan
PMDA-approved (Ozempic)
Canada
Health Canada-approved
Australia
TGA-approved
Regulatory timeline(5)
- 2017-12Ozempic FDA approvalInjectable for T2DM
- 2019-09Rybelsus FDA approvalFirst oral GLP-1 for T2DM
- 2021-06Wegovy FDA approvalInjectable for weight management
- 2025-12Oral Wegovy approvalFirst oral GLP-1 for weight management
- 2025-02-21Shortage resolvedFDA ended shortage, tightened compounding rules
Sources & FAQs
Research sources(5)
Frequently asked questions(5)
Common side effects?
GI: nausea (20-44%), vomiting, diarrhea, constipation. Usually mild, diminish over time. Rare: pancreatitis, gallbladder disease.
Who should NOT take it?
Personal or family history of medullary thyroid carcinoma, MEN 2, or serious allergy to semaglutide or its ingredients. Type 1 diabetes is not a labeled contraindication. Suicidal thoughts require prompt clinical care but are not a labeled semaglutide contraindication.
Is compounded semaglutide available in 2026?
Restricted. The shortage ended February 2025. Qualifying 503A patient-specific compounding may remain possible; documented medical need alone does not permit 503B compounding from bulk semaglutide.
How much weight loss?
Wegovy injection: ~15-17% over 68 weeks. The higher Wegovy HD dose: ~21% over 72 weeks. Oral semaglutide at the obesity dose: ~16.6%. Individual results vary. Dosing is set by your prescriber and the FDA label.
Benefits beyond weight loss?
20-26% CV event reduction, 24% kidney event reduction, anti-inflammatory effects. EVOKE and EVOKE+ did not slow Alzheimer's progression; liver-disease research continues.